Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin, Abhinav Deol, Nikhil C. Munshi, Elizabeth O’Donnell, David Avigan, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Jenna D Goldberg, Jordan M. Schecter, William Deraedt, Sen Hong Zhuang, Jeffrey R. Infante, Dong Geng, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Farah Hossain, Syed Rizvi, Frank Fan, Yi Lin, Thomas G. Martin, Sundar Jagannath
Topics & Concepts
Chimeric antigen receptorAntigenRefractory (planetary science)MedicineOpen labelMultiple myelomaReceptorImmunologyCellImmunotherapyCancer researchBiologyInternal medicineImmune systemClinical trialGeneticsAstrobiologyCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses